Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel

Autor: Kim A. Papp, Jennifer Beecker, Curtis Cooper, Mark G. Kirchhof, Anton L. Pozniak, Juergen K. Rockstroh, Jan P. Dutz, Melinda J. Gooderham, Robert Gniadecki, Chih-ho Hong, Charles W. Lynde, Catherine Maari, Yves Poulin, Ronald B. Vender, Sharon L. Walmsley

Publikováno v: Dermatology and Therapy, Vol 13, Iss 8, Pp 1891-1892 (2023)

Externí odkaz: https://doaj.org/article/df8a010ddfd24de28758f2c5760c3302

Recommendations for defining preventable HIV-related mortality for public health monitoring in the era of Getting to Zero: an expert consensus

Autor: Sara E Croxford, Veronique Martin, Sebastian B Lucas, Robert F Miller, Frank A Post, Jane Anderson, Vanessa J Apea, David Asboe, Garry Brough, David R Chadwick, Simon Collins, Helen Corkin, Gillian Dean, Valerie C Delpech, Maka Gogia, Deborah Gold, Anna Kafkalias, Marilena Korkodilos, Justyna D Kowalska, Jacqueline Lindo, Jens D Lundgren, Lucy Lynch, Esteban Martinez, Niall McDougall, Sarah North, Juergen K Rockstroh, Caroline Sabin, Maria Vidal-Read, Laura J Waters, Ann K Sullivan

Publikováno v: The Lancet HIV. 10:e195-e201

Getting to Zero is a commonly cited strategic aim to reduce mortality due to both HIV and avoidable deaths among people with HIV. However, no clear definitions are attached to these aims with regard to what constitutes HIV-related or preventable mort

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4ef57648f33ea87667e3533a672692c
https://doi.org/10.1016/s2352-3018(22)00363-0

High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence

Autor: Georgios Papatheodoridis, Jordan J. Feld, Massimo Colombo, Juergen K. Rockstroh, David Mutimer, Yiran Hu, Ashley Brown, Christophe Moreno, John F. Dillon, Reem Ghalib, Douglas E. Dylla, Eric Lawitz, Anne F Luetkemeyer, David R. Nelson, Eric Crown, Ira M. Jacobson, Philippe J. Zamor, Richard Skoien, Sandra S. Lovell

Publikováno v: The American Journal of Gastroenterology

INTRODUCTION: Pangenotypic, all-oral direct-acting antivirals, such as glecaprevir/pibrentasvir (G/P), are recommended for treatment of hepatitis C virus (HCV) infection. Concerns exist about the impact on efficacy in patients with suboptimal adheren

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3d09546b54ec35e40995afabb0db929
https://doi.org/10.14309/ajg.0000000000001332

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Autor: Jean-Michel Molina, Kathleen Squires, Paul E Sax, Pedro Cahn, Johan Lombaard, Edwin DeJesus, Ming-Tain Lai, Anthony Rodgers, Lisa Lupinacci, Sushma Kumar, Peter Sklar, George J Hanna, Carey Hwang, Elizabeth Anne Martin, Debbie P. Hagins, Olayemi O. Osiyemi, David James Prelutsky, Moti N. Ramgopal, Anthony John Scarsella, Robin Dretler, Christopher J. Bettacchi, James Sims, Patrick G. Clay, Nicholaos C. Bellos, Melanie A. Thompson, Jose Montero, Cheryl K. McDonald, Catherine Creticos, David Shamblaw, Miguel Mogyoros, Antonio E. Terrelonge, Martin Valdes, Karen T. Tashima, William J. Robbins, Franco Antonio Felizarta, Richard A. Elion, Jihad Slim, Sandra S. Win, Sujata N. Lalla-Reddy, Peter Jerome Ruane, Anthony Mills, Jerry L. Cade, Craig A. Dietz, David Scott Rubin, Cynthia Mayer, Juan Carlos Rondon, Paul P. Cook, Eric Daar, Princy N. Kumar, Susan Swindells, Jose Guillermo Castro, Ivan Melendez-Rivera, Javier O. Morales-Ramirez, Lizette Santiago, Jorge L. Santana-Bagur, Marcelo Martins, Pedro Enrique Cahn, Gustavo D. Lopardo, Norma Porteiro, Mark Theo Bloch, David Alfred Baker, Norman Roth, Richard James Moore, Robert James Finlayson, James McMahon, Armin Rieger, Alexander Zoufaly, Sylvia Hartl, Robert Zangerle, Fiona Smaill, Sharon L. Walmsley, Brian Conway, Anita Rachlis, Graham H.R. Smith, Carlos Perez, Alejandro Afani, Maria Isabel Campos, Carolina Eugenia Chahin, Marcelo Wolff Reyes, Jan Gerstoft, Nina Weis, Alex Lund Laursen, Yazdan Yazdanpanah, Laurent Cotte, Francois Raffi, Philippe Morlat, Pierre-Marie Girard, Christine Katlama, Juergen K. Rockstroh, Keikawus Arasteh, Stefan Esser, Albrecht Stoehr, Hans-Juergen Stellbrink, Matthias Stoll, Dirk Schuermann, Gerd Faetkenheuer, Johannes Bogner, Thomas Lutz, Axel Baumgarten, Hans Jaeger, Andrea Gori, Gabriel Coltan, Felicia Constandis, Simona Manuela Erscoiu, Liviu-Jany Prisacariu, Sorin Rugina, Adrian Streinu-Cercel, Vadim Valentinovich Pokrovsky, Natalia V. Zakharova, Andrey Anatolyevich Shuldyakov, Elena Pavlovna Ryamova, Valeriy Viktorovich Kulagin, Olga Aleksandrovna Tsybakova, Elena Orlova-Morozova, Firaya Nagimova, Evgeniy Voronin, Tatyana Evgenyevna Shimonova, Oleg Anatolyevich Kozyrev, Catherine Orrell, Johannes Jurgens Lombaard, Marleen de Jager, Joaquin Portilla Segorb, Josep Mallolas, Maria Jesus Perez Elias, Josep M. Gatell, Jose Ramon Arribas Lopez, Eugenia Negredo Puigmal, Daniel Podzamczer Palter, Federico Pulido Ortega, Jesus Troya Garcia, Ignacio De los Santos Gil, Juan Berenguer Berenguer, Ian G. Williams, Margaret A. Johnson, Gabriel Schembri, Amanda Clarke, Mark Gompels, Julie Meriel Fox, Steven John Taylor, David Harold Dockrell, Stephen Kegg

Publikováno v: The Lancet HIV. 7:e16-e26

Doravirine is a novel, non-nucleoside reverse transcriptase inhibitor that has shown non-inferior efficacy to ritonavir-boosted darunavir, with a superior lipid profile, in adults with HIV who were treatment naive at week 48 in the phase 3 DRIVE-FORW

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8680b3078cd4f9be32d8a00724f02a77
https://doi.org/10.1016/s2352-3018(19)30336-4

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.

Autor: Karin Neukam, Daniela I Munteanu, Antonio Rivero-Juárez, Thomas Lutz, Jan Fehr, Mattias Mandorfer, Sanjay Bhagani, Luis F López-Cortés, Annette Haberl, Marcel Stoeckle, Manuel Márquez, Stefan Scholten, Ignacio de Los Santos-Gil, Stefan Mauss, Antonio Rivero, Antonio Collado, Marcial Delgado, Juergen K Rockstroh, Juan A Pineda

Publikováno v: PLoS ONE, Vol 10, Iss 4, p e0125080 (2015)

Clinical trials of therapy against chronic hepatitis C virus (HCV) infection including boceprevir (BOC) or telaprevir (TVR) plus pegylated interferon and ribavirin (PR) have reported considerably higher response rates than those achieved with PR alon

Externí odkaz: https://doaj.org/article/e26652369a0c4196ad0dcb9fb3386485